146 related articles for article (PubMed ID: 10503729)
21. [New antiviral agent. Hepatitis B therapy with slight resistance risk].
MMW Fortschr Med; 2003 Dec; 145(51-52):40. PubMed ID: 14974332
[No Abstract] [Full Text] [Related]
22. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
23. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
24. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Wolters LM; Hansen BE; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1007-11. PubMed ID: 12352221
[TBL] [Abstract][Full Text] [Related]
25. [The influence of HBV genotypes on the therapeutic effects of lamivudine in chronic hepatitis B patients].
Tan WT; Deng GH; Wang YM; Dan YJ; Kuang XM
Zhonghua Gan Zang Bing Za Zhi; 2008 Jul; 16(7):540-1. PubMed ID: 18647538
[No Abstract] [Full Text] [Related]
26. Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2008; 51(6):385-93. PubMed ID: 19229115
[TBL] [Abstract][Full Text] [Related]
27. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B.
Kiyosawa K; Tanaka E
J Gastroenterol; 2001 Feb; 36(2):139-41. PubMed ID: 11227673
[No Abstract] [Full Text] [Related]
28. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
[TBL] [Abstract][Full Text] [Related]
29. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
Yang DH; Xie YJ; Liang WF; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
[No Abstract] [Full Text] [Related]
30. Treatment of chronic viral hepatitis.
Main J; McCarron B; Thomas HC
Antivir Chem Chemother; 1998 Nov; 9(6):449-60. PubMed ID: 9865383
[TBL] [Abstract][Full Text] [Related]
31. [Chronic hepatitis-b-virus infections: new options for antiviral therapy].
de Man RA; Honkoop P; Janssen HL; Schalm SW
Ned Tijdschr Geneeskd; 1999 Sep; 143(37):1857-61. PubMed ID: 10526598
[TBL] [Abstract][Full Text] [Related]
32. Viral hepatitis B.
Lai CL; Ratziu V; Yuen MF; Poynard T
Lancet; 2003 Dec; 362(9401):2089-94. PubMed ID: 14697813
[TBL] [Abstract][Full Text] [Related]
33. [Lamivudine treatment for hepatitis B].
Lamivudine Clincal Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):425-8. PubMed ID: 15487066
[No Abstract] [Full Text] [Related]
34. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
35. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
Akman SA; Kose S; Halicioglu O
Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
[TBL] [Abstract][Full Text] [Related]
36. Treatment of chronic hepatitis B infection.
Omata M
N Engl J Med; 1998 Jul; 339(2):114-5. PubMed ID: 9654543
[No Abstract] [Full Text] [Related]
37. A proposed, evidence-based approach to the treatment of chronic Hepatitis B.
Han SH; Durazo FA; Saab S; Tong MJ
J Clin Gastroenterol; 2011 Mar; 45(3):259-66. PubMed ID: 20856136
[TBL] [Abstract][Full Text] [Related]
38. [Laboratory diagnosis of hepatitis B].
Forns X; Sánchez-Tapias JM
Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():7-14. PubMed ID: 11279897
[No Abstract] [Full Text] [Related]
39. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
Tsubota A
J Gastroenterol Hepatol; 2006 Dec; 21(12):1769-71. PubMed ID: 17074012
[No Abstract] [Full Text] [Related]
40. One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.
Kaplan DD; Reddy KR
Am J Gastroenterol; 2002 Sep; 97(9):2465-7. PubMed ID: 12358276
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
